Company type | KGaA with Aktiengesellschaft as partner with unlimited liability |
---|---|
FWB: 1SXP | |
ISIN | DE000A3ENQ51 |
Industry | Healthcare |
Founded | August 1, 2022; 23 months ago (2022-08-01) |
Headquarters | Mainz, Germany |
Key people | Andreas Reisse, CEO Almuth Steinkühler, CFO |
Products | Pharmaceutical drug containment and delivery systems |
Revenue | €899 million (2022/2023)[1] |
Owner | Schott AG |
Number of employees | 4,646 (as of September 30, 2023)[1] |
Divisions |
|
Website | schott-pharma |
Schott Pharma (stylized as SCHOTT Pharma) is a provider of drug containment solutions and delivery systems for injectable drugs.[2][3] Headquartered in Mainz, Germany,[4][5] the company operates in 14 countries.[6]
In 1887, Otto Schott developed borosilicate glass, a form of glassware used to reagent bottles and flasks. From 1911, Schott manufactured borosilicate glass tubing for the production of pharmaceutical ampoules and vials.[7]
Schott Pharma was established as a standalone company in 2022 under the name Schott Pharma AG & Co. KGaA[8][5] through an equity carve-out (or spin-off) from Schott AG, a manufacturer of specialty glass and glass-ceramics.[9][10]
In the same year, the company announced their plans to present an IPO, but this was reportedly postponed to 2023 due to the Ukraine war.[4] In September 2023, Schott Pharma went public on the Frankfurt Stock Exchange. The IPO was initially priced at 27€ per share,[11][12] and a potential valuation of up to 4.1 billion euros,[13] but increased the share price to 30€ the following day.[14] The IPO was the largest of the year in Germany.[15][16] In December 2023, Schott Pharma was included in the SDAX.[17]
This section needs expansion. You can help by adding to it. (June 2024)
|
The company is headquartered in Mainz and operates in 16 locations across 14 countries.[18]
Schott Pharma develops and manufactures drug containment solutions and delivery systems for injectable drugs, which it supplies to companies in the biotechnology and pharmaceutical industries.[23]
Its business is divided into two divisions:
Schott Pharma is a subsidiary of SCHOTT AG, who has controlling shares of 77%(as of 2023: 77%).[16][14] SCHOTT AG is owned by the Carl Zeiss Foundation.[21]
Schott Pharma was listed on the Frankfurt Stock Exchange's SDAX in 2023.
This section needs expansion. You can help by adding to it. (June 2024)
|
In 2023 SCHOTT AG appointed a Supervisory Board for the subsidiary Schott Parma AG as follows:[27][28]
This section needs expansion. You can help by adding to it. (June 2024)
|
2022/23 | 2023/24 | ||
---|---|---|---|
Turnover | |||
Net Profit | |||